Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis

J Diabetes Res. 2020 Mar 6:2020:8768954. doi: 10.1155/2020/8768954. eCollection 2020.

Abstract

Despite different classes of antidiabetic medications available for the management of patients with diabetes, efforts are underway to identify novel and safer antihyperglycemic agents with higher potency and increased tolerability. Imeglimin is a promising antidiabetic agent that has shown to have significant antihyperglycemic effects in studies, although it has not been approved yet. There is growing evidence that imeglimin improves glucose homeostasis in the diabetic milieu; however, the precise molecular mechanisms are still not elucidated. In this review, we discuss various molecular pathways by which imeglimin exerts its antihyperglycemic effects and improves glucose homeostasis in the diabetic milieu.

Publication types

  • Review

MeSH terms

  • Animals
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Homeostasis
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Triazines / therapeutic use*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Triazines
  • imeglimin